Citadel Advisors’s Zevra Therapeutics ZVRA Stock Holding History
Bought
Maintained
Sold
Other funds holding ZVRA
Citadel Advisors's ZVRA Position: Q3 2026 in Review
Citadel Advisors increased its Zevra Therapeutics (ZVRA) stake by 3,590% in Q3 2026, buying an estimated $5.18M and bringing the position to 448,934 shares worth $4.92M. The position accounts for ﹤0.01% of the portfolio, ranked #4870.
Citadel Advisors first reported a position in ZVRA in Q4 2019 and has held it in 21 quarters since. The position peaked at $7.55M in Q4 2025. 176 funds tracked by Wall St. Rank hold ZVRA as of Q3 2026.
- Citadel Advisors held 448,934 shares of Zevra Therapeutics worth $4.92M as of Q3 2026.
- Citadel Advisors bought 436,767 Zevra Therapeutics shares in Q3 2026, an estimated $5.18M.
- Zevra Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q3 2026, its #4870 holding.
- Citadel Advisors first reported a position in Zevra Therapeutics in Q4 2019 and has held it in 21 quarters since.
- Citadel Advisors's Zevra Therapeutics position peaked at $7.55M in Q4 2025.
- 176 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2026.
Based on Citadel Advisors's 13F filing for Q3 2026, filed 16 Nov 2026.